Understand the source comparison
Alopecia Peptides 2026 Update: Comparison of Mechanisms
Before selecting a peptide protocol, understanding the mechanistic differences determines realistic expectations and appropriate use cases. The table below compares the three peptides with the strongest 2024–2026 clinical backing. | Peptide | Primary Mechanism
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understanding the mechanistic differences determines realistic expectations and appropriate use cases. The table below compares the three peptides with the strongest 2024–2026 clinical backing.
- | Peptide | Primary Mechanism | Target Tissue | Clinical Evidence (2024–2026) | Optimal Delivery | Best Use Case | Professional Assessment ||—|—|—|—|—|—|| GHK-Cu | TGF-beta suppression, VEGF upregulation | Dermal papilla | 22% density improvement at 20 weeks (Seoul National, 2025) | Microneedling 1.5mm + topical | Androgenetic alopecia stages II–V | Strongest evidence for pattern hair loss; works even in advanced miniaturisation || TB-500 | Keratinocyte migration, actin remodelling | Follicular bulge | 18% density increase at 6 months (Korean cohort, 2024) | Intradermal injection 2mg monthly | Early-stage androgenetic alopecia | Best for halting progression; less effective in fully miniaturised zones || KPV | NF-kappa-B inhibition, melanocortin activation | Perifollicular immune niche | 61% partial regrowth in alopecia areata patches (Miami, 2025) | Topical application | Autoimmune alopecia (areata, totalis) | Not relevant for androgenetic alopecia; targets inflammation, not DHT pathwa